The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Pharmacological Inhibition of Diabetic Retinopathy
Open accessAbstract
Effects of aminoguanidine and aspirin on the development of retinopathy have been examined in 5-year studies of diabetic dogs. Either agent was administered daily in doses of 20–25 mg · kg−1 · day−1. Because severity of hyperglycemia greatly influences development of the retinopathy, special effort was devoted to maintaining comparable glycemia in experimental and control groups. The retinal vasculature was isolated by the trypsin digest method, and retinopathy was assessed by light microscopy. Diabetes for 5 years resulted, as expected, in saccular capillary aneurysms, pericyte ghosts, acellular capillaries, retinal hemorrhages, and other lesions. Administration of aminoguanidine essentially prevented the retinopathy, significantly inhibiting the development of retinal microaneurysms, acellular capillaries, and pericyte ghosts compared with diabetic controls. Aspirin significantly inhibited the development of retinal hemorrhages and acellular capillaries over the 5 years of study, but had less effect on other lesions. Although diabetes resulted in significantly increased levels of advanced glycation end products (AGEs) (namely, pentosidine in tail collagen and aorta, and Hb-AGE), aminoguanidine had no significant influence on these parameters of glycation. Nitration of a retinal protein was significantly increased in diabetes and inhibited by aminoguanidine. The biochemical mechanism by which aminoguanidine has inhibited retinopathy thus is not clear. Aminoguanidine (but not aspirin) inhibited a diabetes-induced defect in ulnar nerve conduction velocity, but neither agent was found to influence kidney structure or albumen excretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Dinis, T. C. P., Madeira, V. M. C., & Almeida, L. M. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1485 · Cited by 2,719
Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking
Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., & Cerami, A. (1986) · Science · doi:10.1126/science.3487117 · Cited by 1,146
Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction
Corbett, J. A., Tilton, R. G., Chang, K., Hasan, K. S., Ido, Y., Wang, J. L., Sweetland, M. A., Lancaster, J. R., Williamson, J. R., & McDaniel, M. L. (1992) · Diabetes · doi:10.2337/diab.41.4.552 · Cited by 628
Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.
Hammes, H. P., Martin, S., Federlin, K., Geisen, K., & Brownlee, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11555 · Cited by 524
Progression of Incipient Diabetic Retinopathy During Good Glycemic Control
Engerman, R. L., & Kern, T. S. (1987) · Diabetes · doi:10.2337/diab.36.7.808 · Cited by 490 · cited 2×
“Trypsin digests of retinal vessels were stained with periodic acid Schiff and hematoxylin for evaluation of retinopathy (1,6,27).”
BackgroundMethodSelf-citationMechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine
Edelstein, D., & Brownlee, M. (1992) · Diabetes · doi:10.2337/diab.41.1.26 · Cited by 360
Relationship of Microvascular Disease in Diabetes to Metabolic Control
Engerman, R., Bloodworth, J. M. B., & Nelson, S. (1977) · Diabetes · doi:10.2337/diab.26.8.760 · Cited by 322
Self-citationTilton, R. G., Chang, K., Hasan, K. S., Smith, S. R., Petrash, J. M., Misko, T. P., Moore, W. M., Currie, M. G., Corbett, J. A., McDaniel, M. L., et al. (1993) · Diabetes · doi:10.2337/diab.42.2.221 · Cited by 293
Experimental Galactosemia Produces Diabetic-like Retinopathy
Engerman, R. L., & Kern, T. S. (1984) · Diabetes · doi:10.2337/diab.33.1.97 · Cited by 278
Self-citation
Cited by
Inflammation in diabetic retinopathy
Tang, J., & Kern, T. S. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.05.002 · Cited by 1,116
Self-citationFrank, R. N. (2004) · New England Journal of Medicine · doi:10.1056/nejmra021678 · Cited by 891
Diabetic Retinopathy and Diabetic Macular Edema
Ciulla, T. A., Amador, A. G., & Zinman, B. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2653 · Cited by 836
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts
Thornalley, P. J. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.013 · Cited by 682
Metadata
- Authors
- Kern, T. S., & Engerman, R. L.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2001-07-01
- Volume
- 50
- Issue
- 7
- Pages
- 1636-1642
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2140794335
- Cited by
- 277
- References
- 49
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Inhibition of Diabetic Retinopathy. https://app.cochat.ai/papers/10.2337/diabetes.50.7.1636
- The paper
- Kern, T. S., & Engerman, R. L. (2001). Pharmacological Inhibition of Diabetic Retinopathy. Diabetes. https://doi.org/10.2337/diabetes.50.7.1636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.